You are here

  • Home
  • Archive
  • Volume 12, Issue 1
  • CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

Citation Tools

Article menu

Download PDFPDF

HIV/AIDS
Protocol
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gengiah TN, Abdool Karim Q, Harkoo I, et al
CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women
BMJ Open 2022;12:e052880. doi: 10.1136/bmjopen-2021-052880